Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has significant expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who will continue to lead the business. The investment is being made from Inflexion Enterprise Fund V.

Nottingham-based Upperton was founded in 1999 and conducts formulation and analytical development and clinical trial manufacturing services for small to mid-sized pharma clients. Upperton uses its expertise to develop a wide range of finished dosage formats for their clients (typically during early phase clinical trials), with this often making the difference between success and failure for the pharma company. Alongside dosage form development, Upperton also specialises in spray drying, a particle engineering technology which can be used to ensure targeted delivery of drugs to the lungs and nasal cavity or to provide solutions to pharma clients who have challenges with poorly soluble molecules.

As part of the investment, Inflexion will support Upperton in expanding its scale and capabilities, commencing with the build of a new, larger manufacturing facility which will allow Upperton to extend its services to support later stages of clinical trials and commercial manufacturing.